MM-329: Evaluation of Immunophenotype of the Non-Neoplastic Plasma Cell Compartment and Post-Therapy Immunomodulation to Understand Nuances in MRD Assessment of Multiple Myeloma Using Next-Generation Flow Cytometry

A deeper understanding of the normal plasma cell (PC) compartment and changes in the immunophenotypic profile post-treatment is required to assess low levels of residual disease in multiple myeloma (MM) using multiparametric flow cytometry. The expression profile of selective antigens on normal and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2021-09, Vol.21, p.S436-S437
Main Authors: Gupta, Ritu, Das, Nupur, Dahiya, Meetu, Rai, Sandeep, Singh, Saroj, Prajapati, Vijay K., Sahoo, Ranjit k., Gogia, Ajay, Sharma, Atul, Kumar, Lalit
Format: Article
Language:English
Subjects:
immunomodulation
multiple myeloma
NGF
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A deeper understanding of the normal plasma cell (PC) compartment and changes in the immunophenotypic profile post-treatment is required to assess low levels of residual disease in multiple myeloma (MM) using multiparametric flow cytometry. The expression profile of selective antigens on normal and aberrant plasma cells prior to and following anti-myeloma therapy was assessed to ascertain its relevance in MRD assessment. This is a prospective analysis of 702 patients with the diagnosis of MM (January 2015 to June 2020). The study was conducted at a tertiary care cancer center. A total of 702 cases (321 treatment naïve; 321 post-therapy; 60 control samples) were evaluated. Sixty samples from non-MM staging marrow were assessed to study antigenic profiles of normal PC. Bone marrow samples were collected in EDTA and processed within 6 hours of collection per the consensus recommendation from the Euro-flow protocol using two tube 8-color/single tube 10-color panel. An aberrant PC cluster was defined by presence of >30 plasma cells with light chain restriction and/or aberrant immunophenotypes. 1. Expression profile of antigens on the polyclonal PC compartment; 2. Post-therapy immunomodulation in MM. Polyclonal PC were observed in 65.42% of treatment naïve samples compared to 88.16% post-treatment samples (p=0.001). Frequency of aberrant expression of markers in polyclonal PC was higher at follow-up time point: CD45 (33% vs 38%; p=0.6), CD19 (19% vs 41%; p=0.001), CD56 (14% vs 41%; p
ISSN:2152-2650
2152-2669
DOI:10.1016/S2152-2650(21)01973-X